LXEO Lexeo Therapeutics, Inc. Common Stock
Healthcare$5.11-2.29%ClosedMarket Cap: $401.2M
As of 2026-05-25
Valuation
P/E (TTM)
—
PEG
—
P/B
1.79
P/S
0.00
EV/EBITDA
-3.86
DCF Value
$0.95
FCF Yield
-24.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-47.5%
ROA
-35.0%
ROIC
-40.9%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-22.3M | $-20.2M | $— | — |
| Q4 null | $0.00 | NaN% | $-23.1M | $-20.9M | $— | — |
| FY null | $0.00 | NaN% | $-109.3M | $-100.0M | $— | — |
| Q3 null | $0.00 | NaN% | $-21.6M | $-20.3M | $— | — |
| Q2 null | $0.00 | NaN% | $-30.7M | $-26.1M | $— | — |
| Q1 null | $0.00 | NaN% | $-33.8M | $-32.7M | $— | — |
| Q4 null | $0.00 | NaN% | $-27.4M | $-25.9M | $— | — |
| FY null | $0.00 | NaN% | $-105.8M | $-98.3M | $— | — |
| Q3 null | $0.00 | NaN% | $-31.5M | $-29.5M | $— | — |
| Q2 null | $0.00 | NaN% | $-23.6M | $-21.2M | $— | — |
| Q1 null | $0.00 | NaN% | $-23.3M | $-21.7M | $— | — |
| Q4 2023 | $0.00 | NaN% | $-15.0M | $-14.2M | $-0.52 | — |